Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triethylene Glycol SCHEMBL10570660 | 0.87 | MEN1 (0.46) | TSHRMAPK1MEN1KMT2ATHRB | |
| SCHEMBL9122599 | 0.87 | TSHR (0.33) | TSHR | |
| SCHEMBL9911589 | 0.84 | MEN1 (0.33) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL15713293 | 0.83 | TSHR (0.52) | TSHRMAPK1MEN1KMT2ATHRB | |
| Ethylene Glycol SCHEMBL10570614 | 0.81 | ALDH1A1 (0.50) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL2851474 | 0.79 | TSHR (0.48) | TSHRMAPK1MEN1KMT2ATHRB | |
| SCHEMBL6828573 | 0.78 | MEN1 (0.47) | TSHRMAPK1MEN1KMT2ATHRB | |
| SCHEMBL8483647 | 0.77 | TSHR (0.50) | TSHRMEN1KMT2ATHRBHTT | |
| SCHEMBL17739935 | 0.75 | CA2 (0.32) | TSHR | |
| SCHEMBL10570622 | 0.75 | ALDH1A1 (0.36) | TSHRMEN1KMT2ATHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114533593-B | Cosmetic in the form of a liquid paste at normal temperature and composition of biodegradable copolymers | 莹特丽股份公司 | 2024-06-25 | — | — | CN | claimed |
| CN-114533593-A | Composition of liquid-pasty cosmetic and biodegradable copolymer at room temperature | 莹特丽股份公司 | 2022-05-27 | — | — | CN | claimed |
| US-9353135-B2 | Silicone compound and a use thereof | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-05-31 | — | — | US | disclosed |
| US-20160121101-A1 | Medical leads | MEDTRONIC, INC. | 2016-05-05 | — | — | US | disclosed |
| US-9284338-B2 | Silicone compound and a use thereof | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-03-15 | — | — | US | disclosed |
| US-20150266905-A1 | SILICONE COMPOUND AND A USE THEREOF | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-9066981-B2 | Actinically-crosslinkable siloxane-containing copolymers | NOVARTIS AG (CH) | 2015-06-30 | — | — | US | disclosed |
| EP-1650214-B1 | Silicon compound | CHISSO CORP (JP) | 2009-11-04 | — | — | EP | disclosed |
| US-7319129-B2 | Silsesquioxane derivative and process for producing the same | CHISSO CORPORATION (JP) | 2008-01-15 | — | — | US | disclosed |
| US-7256243-B2 | Silicon compound | CHISSO CORPORATION (JP) | 2007-08-14 | — | — | US | disclosed |
| EP-1799739-A1 | GELS | AorTech Biomaterials Pty Ltd (AU) | 2007-06-27 | — | — | EP | disclosed |
| EP-1650214-A2 | Silicon compound | CHISSO CORPORATION (JP) | 2006-04-26 | — | — | EP | disclosed |
| WO-2006034547-A1 | GELS | AORTECH BIOMATERIALS PTY LTD (AU) | 2006-04-06 | — | — | WO | disclosed |
| US-20060052623-A1 | Having two cyclotetrasiloxne rings connected by O-Si groups obtained through hydrolysis and condensation of trifunctional hydrolyzable silicon compounds; functionalization; fireproofing, thermostability, weathproofing, photostability, dielectric, hardness, strength and chemical resistance | CHISSO CORPORATION (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20050250925-A1 | Silicon compound | JNC CORPORATION (JP) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052623-A1 | Having two cyclotetrasiloxne rings connected by O-Si groups obtained through hydrolysis and condensation of trifunctional hydrolyzable silicon compounds; functionalization; fireproofing, thermostability, weathproofing, photostability, dielectric, hardness, strength and chemical resistance | STS, PFAS, POLQ | TSHR 2188/4885MAPK1 3939/4885MEN1 4800/4885 |
| US-20150266905-A1 | SILICONE COMPOUND AND A USE THEREOF | PRMT1, PRMT5, FEM1B | TSHR 1872/4885MAPK1 871/4885MEN1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.